التفاصيل البيبلوغرافية
| العنوان: |
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). |
| المؤلفون: |
Descourt, Renaud, Greillier, Laurent, Perol, Maurice, Ricordel, Charles, Auliac, Jean-Bernard, Falchero, Lionel, Gervais, Radj, Veillon, Rémi, Vieillot, Sabine, Guisier, Florian, Marcq, Marie, Justeau, Grégoire, Bigay-Game, Laurence, Bernardi, Marie, Fournel, Pierre, Doubre, Hélène, Pinsolle, Julian, Amrane, Karim, Chouaïd, Christos, Decroisette, Chantal |
| المصدر: |
Cancer Immunology, Immunotherapy; Jan2023, Vol. 72 Issue 1, p91-99, 9p |
| مصطلحات موضوعية: |
NON-small-cell lung carcinoma, BRAIN metastasis, PEMBROLIZUMAB, NEUTROPHIL lymphocyte ratio, PROGRESSION-free survival |
| مصطلحات جغرافية: |
FRANCE |
| مستخلص: |
Background: Few real-world data are available in patients with advanced metastatic non-small cell lung cancer (NSCLC) treated with first-line immunotherapy, particularly in those with brain metastases at treatment initiation. Methods: This was a national, retrospective, multicenter study that consecutively included all patients with PD-L1-positive (tumor proportion score ≥ 50%) advanced NSCLC who initiated first-line treatment with pembrolizumab as a single agent between May 2017 (date of availability of pembrolizumab in this indication in France) to November 22, 2019 (approval of the pembrolizumab-chemotherapy combination). Data were collected from medical records with local response assessment. Results: The cohort included 845 patients and 176 (20.8%) had brain metastases at diagnosis. There were no significant differences in outcomes for patients with and without brain metastases: 9.2 (95% CI 5.6–15) and 8 (95% CI 6.7–9.2, p = 0.3) months for median progression-free survival (PFS) and, 29.5 (95% CI 17.2–NA) and 22 (95% CI 17.8–27.1, p = 0.3) months for median overall survival (OS), respectively. Overall response rates were 47% and 45% in patients with and without cerebral metastases. In multivariate analysis, performance status 2–4 vs. 0–1 and neutrophil-to-lymphocyte ratio ≥ 4 vs. < 4 were the main independent negative factors for OS; brain metastasis was not an independent factor for OS. Conclusion: In this large multicenter cohort, nearly 20% of patients initiating pembrolizumab therapy for advanced NSCLC had cerebral metastases. There was no significant difference in response rates, PFS and OS between patients with and without brain metastases. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Immunology, Immunotherapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder